Keyphrases
Pulmonary Arterial Hypertension
100%
Pivotal Trial
100%
Spironolactone
100%
Hypertension Patients
27%
Patient Demographics
18%
6-minute Walk Distance (6MWD)
18%
Clinical Worsening
18%
World Health Organization Functional Class
18%
Adverse Effects
9%
Pulmonary Vascular
9%
Improved Outcomes
9%
Cardiac Index
9%
Diuretics
9%
Disease Severity
9%
Patient Outcomes
9%
All-cause Mortality
9%
Disease Process
9%
Severe Heart Failure
9%
Large Cohort
9%
Receptor Function
9%
Vascular Remodeling
9%
Dyspnea Score
9%
Vascular Pathology
9%
Arterial Pressure
9%
Right Heart Failure
9%
Hypertension Disease
9%
Propensity Analysis
9%
Pulmonary Microvascular Endothelial Cells (PMVECs)
9%
Current Analysis
9%
Hyperaldosteronism
9%
Endothelin B Receptor
9%
Treprostinil
9%
Cardiopulmonary Hemodynamics
9%
Left Heart Disease
9%
Biochemistry, Genetics and Molecular Biology
Endothelin Receptor Type B
9%
Pharmacology, Toxicology and Pharmaceutical Science